Brief: Advicenne's ADV7103 Gets ODD For Distal Renal Tubular Acidosis

Advicenne SA

13/12/2022 06:03

Dec 13 (Reuters) - ADVICENNE SA  ALDVI.PA :
    * ADVICENNE OBTAINS ORPHAN DRUG DESIGNATION FOR ADV7103 IN
THE
UNITED STATES FOR THE TREATMENT OF DISTAL RENAL TUBULAR ACIDOSIS
(DRTA)
    * ANNOUNCED TODAY THAT ADV7103 HAS BEEN GRANTED ORPHAN DRUG
DESIGNATION (ODD) STATUS FOR TREATMENT OF DISTAL RENAL TUBULAR
ACIDOSIS (DRTA)
    * DESIGNATION WAS ISSUED BY US FOOD AND DRUG ADMINISTRATION
(US
FDA)
    * IS ALSO STUDYING POSSIBILITY OF APPLYING FOR AN ORPHAN
DESIGNATION IN CYSTINURIA INDICATION IN UNITED STATES

Source text for Eikon:  ID:nBw9CfpV6a 
Further company coverage:  ALDVI.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))